

REFERENCES

- A Cameron, M Ewen, D Ross-Degnan, D Ball, R Laing. (2008). Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet: 5. doi: 10.1016/S0140-6736(08)61762-6 1
- A, Cameron, M, Ewen, Ross-Degnan, D, Ball, D, & Laing, R. (2009). Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet, 373, 9659:240-249. doi: 10.1016/S0140-6736(08)61762-6
- Aalto-Setälä, V. (2008). The impact of generic substitution on price competition in Finland. Eur J Health Econ, 9, 2:185-191. doi: 10.1007/s10198-007-0059-0
- Alexandra Cameron a, Ilse Roubos b, Margaret Ewen c, Aukje K Mantel-Teeuwisse b, Hubertus GM Leufkens b & Richard O Laing (2008). Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bulletin of the World Health Organization, 89: 412-421. doi: 10.2471/BLT.10.084327
- Ali, G. K., & Yahia, Y. (2012). Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority. East Mediterr Health J, 18, 8: 811-820.
- Ali, G., & Yahia, Y. (2012). Controlling medicine prices in Sudan: the challenge of the recently established Medicines Regulatory Authority Eastern Mediterranean Health Journal, 18, 8: 811.
- Anson, A., Ramay, B., de Esparza, A. R., & Bero, L. (2012). Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health, 8: 22. doi: 10.1186/1744-8603-8-22
- Babar, Z. D., & Izham, M. I. (2009). Effect of privatization of the drug distribution system on drug prices in Malaysia. Public Health, 123, 8: 1-2. doi: 10.1016/j.puhe.2009.06.011
- Babar, Z. U., Izham, M. I., Singh, H., Bukahri, N. I., & Creese, A. (2007). Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med, 4, 3: 2. doi: 10.1371/journal.pmed.0040082
- Babar, Zaheer Ud Din, Ibrahim, Mohamed Izham Mohamed, Singh, Harpal, Bukahri, Nadeem Irfan, & Creese, Andrew. (2007). Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia. PLoS Med, 4, 3: e82. doi: 10.1371/journal.pmed.0040082
- Ball, D. (2011). The Regulation of Mark-ups in the pharmaceutical Supply Chain *Review Series on Pharmaceutical Pricing Policies and Interventions*: World Health Organization and Health Action International
- Bate, R., Jin, G. Z., & Mathur, A. (2011). Does price reveal poor-quality drugs? Evidence from 17 countries. J Health Econ, 30, 6: 1. doi: 10.1016/j.jhealeco.2011.08.006

- Bertoldi, A. D., Helfer, A. P., Camargo, A. L., Tavares, N. U., & Kanavos, P. (2012). Is the Brazilian pharmaceutical policy ensuring population access to essential medicines? Global Health, 8: 6. doi: 10.1186/1744-8603-8-6
- Cameron, A, Roubos, I, Ewen, M., A, Teeuwisse., Leufkens, H., & Laing, R. (2011). Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bulletin of the World Health Organization 89: 412-421. doi: 10.2471/BLT.10.084327
- Cameron, A., Ewen, A. , Teeuwisse, H. , Leufkens, Laing, R., & Roubos, I. (2011). Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bulletin of the World Health Organization, 89, 6: 412-421.
- Cameron, A., Ewen, M., Auton, Martin, & Dele , A. (2011). The World Medicines Situation 2011: Medicines Prices, Availability and Affordability. from http://www.who.int/nha/docs/world_medicine_situation.pdf
- Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009). Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet, 373, 9659: 240-249. doi: 10.1016/S0140-6736(08)61762-6
- Cameron, A., Ewen, M., Ross, D. L., Ball, D., & Laing, R. (2009). Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet, 373, 9664: 240 - 249. doi: 10.1016/S0140-6736(08)61762-6
- Cameron, A., Mantel-Teeuwisse, A. K., Leufkens, H. G., & Laing, R. O. (2012). Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health, 15, 5: 664-673. doi: 10.1016/j.jval.2012.04.004
- Commission, Federal Trade. (2010). Pay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions: Federal Trade Commission, USA.
- Dalen, DagMorten. (2006). Price regulation and generic competition in the pharmaceutical market. The European Journal of Health Economics, 7, 3: 204-211.
- DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. J Health Econ, 22, 2: 151-185. doi: 10.1016/S0167-6296(02)00126-1
- Espin, Rovira, Joan, & Labry, Antonio Olry de. (2011). Pharmaceutical Pricing Policies and Interventions; External Reference Pricing. from <http://www.haiweb.org/medicineprices/24072012/ERPfinalMay2011.pdf>
- Ewen, M., Laing, R., Nouguchi, N., & Gelders, S. (2006). Price, availability and affordability : An international comparison of chronic disease medicines. Health Action International.

- Feldman, R., & Lobo, F. (2012). Competition in prescription drug markets: the roles of trademarks, advertising, and generic names. Eur J Health Econ. doi: 10.1007/s10198-012-0414-7
- FMoF, NSB, ADB (2009). *Sudan Damily House Hold Survey*. NSB web: National Statistic Bureau
- FMoH. (2010). *Sudan Pharmaceutical Country Prodile*. WHO.
- Frost, Laura J., & Reich, Michael R. (2008). How do good health technologies get to poor people in poor countries? AccessHarvard Series on Population and International Health: Harvard Center for Population and Development Studies.
- Gelders, S., Ewen, M., Noguchi, N., & Laing, R. (2005). Price, availability and affordability : An international comparison of chronic disease medicines.
- HAI. (2010). Life-saving insulin largely unaffordable - A one day snapshot of the price of insulin across 60 countries.
- Huckfeldt, Peter J. Knittel, Christopher R. (2011). Pharmaceutical use following generic entry : paying less and buying less (ed.). Cambridge, MA: Cambridge, MA : National Bureau of Economic Research.
- Kong, Ying. (2004). The price premium of generic to brand-names and pharmaceutical price index. Applied economics, 36, 7: 731-737.
- Kotwani, A. (2009). Availability, price and affordability of asthma medicines in five Indian states. Int J Tuberc Lung Dis, 13, 5: 574-579.
- Kotwani, A., Ewen, M., & Laing, R. (2006). A standardized methodology to measure medicine prices, availability, affordability and price components in developing and transitional countries. The International Journal of Tuberculosis and Lung Disease, 9, 3: A57-A58. doi: Doi 10.1016/S1098-3015(10)64482-8
- Lexchin, J. (2004). The effect of generic competition on the price of brand-name drugs. Health Policy, 68, 1: 47-54. doi: 10.1016/j.healthpol.2003.07.007
- LM Niëns, a, E Van de Poel, a, A Cameron, b, M Ewen, c, Laingb, R, & Brouwera, & WBF. (2012). Practical measurement of affordability: an application to medicines. Bull World Health Organ 90, 3: 219–227. .
- Madden, J. M., Meza, E., Ewen, M., Laing, R. O., Stephens, P., & Ross-Degnan, D. (2010). Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica, 27, 4: 291-299.
- Mahgoub, Izham (2009). Do systems contribute to the sustainability of the Revolving Drug Fund (RDF) in Sudan. Sudanese Journal of Public Health, 4, 2: 288-295.
- Meiners, C., Sagaon-Teyssier, L., Hasenclever, L., & Moatti, J. P. (2011). Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth? PLoS One, 6, 8: e23478. doi: 10.1371/journal.pone.0023478

- NHIF. (2012). *The Full Tender Report: Second Half 2012*. Khartoum, Sudan.
- NSB. (2011). *The Fifth Sudan Census, 2008: 2011 projection*. NSB website: National Statistics Bureau Retrieved from <http://www.cbs.gov.sd/en/taxonomy/term/17>.
- NSB. (2012). *Consumer Price Index*. Website: Retrieved from <http://www.cbs.gov.sd/en/node/127>.
- Nunan, M., & Duke, T. (2011). Effectiveness of pharmacy interventions in improving availability of essential medicines at the primary healthcare level. Trop Med Int Health, 16, 5: 647-658. doi: 10.1111/j.1365-3156.2011.02748.x
- O'Connell, K. A., Gatakaa, H., Poyer, S., Njogu, J., Evance, I., Munroe, E., . . . Chavasse, D. (2011). Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J, 10: 326. doi: 10.1186/1475-2875-10-326
- Penchansky, Roy, & Thomas, J. William. (1981). The Concept of Access: Definition and Relationship to Consumer Satisfaction. Medical Care, 19, 2: 127-140.
- Puig Junoy, J. . (2010). Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics, 28, 8: 649-663. doi: 10.2165/11535360-000000000-00000
- Russo, G. McPake, B. (2010). Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings. Health Policy Plan, 25, 1: 70-84. doi: 10.1093/heapol/czp042
- Scherer, F. M. (2004). The pharmaceutical industry--prices and progress. N Engl J Med, 351, 9: 927-932. doi: 10.1056/NEJMp040117
- Seiter, A. (2010). A Practical Approach to Pharmaceutical Policy (ed.): The World Bank.
- Sibbald, B. (2005). Patent-drug price board to review guidelines. CMAJ, 172, 9: 1169. doi: 10.1503/cmaj.050331
- Simoens, S. (2007). International comparison of generic medicine prices. Curr Med Res Opin, 23, 11: 2647-2654. doi: 10.1185/030079907X233395
- UN. (2012). The Global Partnership for Development: Making Rhetoric a Reality MDG Gap Task Force Report.
- WHO/HAI. (2008a). Measuring Medicine prices, availability, affordability and price components. 293.
- WHO/HAI. (2008b). Measuring medicine prices, availability, affordability and price components. second edition. from http://www.who.int/medicines/areas/access/OMS_Medicine_prices.pdf
- WHO/HAI. (2008c). measuring medicine prices, availability, affordability, and price component (ed.).

- WHO/HAI. (2008d). Measuring Medicines prices, availability, affordability and price componenets 293.
- Yang, H., Dib, H. H., Zhu, M., Qi, G., & Zhang, X. (2010). Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy Plan, 25, 3: 219-229. doi: 10.1093/heapol/czp056

BIOGRAPHY

Author : Mr. Mohammed Yusuf Ahmed Musa
Country : Sudan
Nationality : Sudanese
Education . : Bachelor of Pharmacy, 2001 University of Khartoum,
Sudan.
Work : work at National Health Insurance Fund, since 2002
until now.
2002-2004 : Drug Supply Manager NHIF, West Darfur State
2005-2006 : Head of Drug Supply in NHIF, H.Q
2007 : Drug Supply Manager NHIF, H.Q
2008 to now: director NHIF, West Darfur
Address : Baladia St, National Health Insurance Fund H.Q,
Khartoum, Sudan – P.O 13267 T: +249912376248
Email: mohyuaif@yahoo.com
